default author photo

Kelly E. Dooley

Vanderbilt University - Medical Center

SCHOLARLY PAPERS

2

DOWNLOADS

194

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Simultaneous Initiation of Dolutegravir-Based Antiretroviral Treatment and Once-Weekly Rifapentine and Isoniazid (3HP) for Tuberculosis Prevention in Antiretroviral-Naïve People with HIV: A Phase 1/2 Trial

Number of pages: 22 Posted: 12 Sep 2024
Ethel Derby Weld, Trevor Beattie, Jayajothi Moodley, Manasa Mapendere, Isadora Salles, Belen Perez Solans, Bareng A.S. Nonyane, Lubbe Wiesner, Tanya Nielson, Vinodh Edward, Violet Chihota, Radojka M. Savic, Kelly E. Dooley, Richard E. Chaisson, Gavin Churchyard, DOLPHIN-TOO Study Team and UNITAID IMPAACT4TB Research Group
Johns Hopkins University - Division of Clinical Pharmacology, Aurum Institute, Aurum Institute, Aurum Institute, Johns Hopkins University, University of California, San Francisco (UCSF) - Department of Bioengineering and Therapeutic Sciences, Johns Hopkins University - Bloomberg School of Public Health, University of Cape Town (UCT), Aurum Institute, Aurum Institute, Aurum Institute, University of California, San Francisco (UCSF) - Department of Bioengineering and Therapeutic Sciences, Vanderbilt University - Medical Center, Johns Hopkins University, Aurum Institute, Independent and Independent
Downloads 131 (558,171)

Abstract:

Loading...

Tuberculosis, TB Preventive Treatment, HIV/AIDS, Drug-Drug Interaction Study

2.

Final 18-month Outcomes of a Trial of Four-Month Rifapentine Regimens With or Without Moxifloxacin for Tuberculosis

Number of pages: 18 Posted: 20 Feb 2026
Patrick PJ Phillips, Ekaterina V. Kurbatova, Susan E. Dorman, Anne E. Purfield, Nicole E. Brown, Deron C. Burton, Angela M. Starks, Melinda Dunn, Scott Burns, James E. Posey, Lauren Cowan, Katherine Burri Klein, Mathew Ezewudo, Kelly E. Dooley, Radojka M. Savic, Joseph Akol, Carole Wallis, Nguyet Le, Alexandra Apollon, Claire Sadowski, Nigel A. Scott, Erin Sizemore, Kia E. Bryant, Wendy Carr, Andrew Vernon, Richard E. Chaisson, Susan Swindells and Payam Nahid
University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Centers for Disease Control and Prevention (U.S., Medical University of South Carolina, Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Vanderbilt University - Medical Center, University of California, San Francisco (UCSF) - Department of Bioengineering and Therapeutic Sciences, Case Western Reserve University, Bio Analytical Research Corporation South Africa (BARC SA), National Lung Hospital, Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Johns Hopkins University, University of Nebraska Medical Center and University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis
Downloads 63 (1,010,164)

Abstract:

Loading...

tuberculosis, non-inferiority, rifapentine, moxifloxacin